Debt is smaller than equity and it can meet short-term obligations.
Metrics · D/E ~68% · Current Ratio 1.03
💲Is the price expensive now?
Not cheap (fair to slightly pricey)
Because it is a good, popular company, those expectations are already priced in.
Metrics · P/E 29.3 · P/B 7.5
💡Blue-chip healthcare (pharma + MedTech), a 64-yr Dividend King. Solid margins (27% op, 26% ROE), low debt; talc suits and Stelara's patent cliff are key risks.
Compiled from public financial data. Not a recommendation to buy or sell any security. · Source: stockanalysis (margins, debt, liquidity, P/B are TTM), as of 2026-07-17
Business Summary · Key Value Metrics
A global healthcare company built on two wings — pharmaceuticals (Innovative Medicine) and medical devices (MedTech). Having spun off its consumer arm Kenvue, it now focuses on drugs and devices. TTM revenue is $96.4B with a 27.6% operating margin. 64 consecutive years of dividend increases.
Current Price
$253.04
+1.23%+$3.07· Close 2026-07-17
Analyst Consensus Target (external reference)
$269.95
Avg. of 23 external analysts · stockanalysis (23-analyst consensus, Buy)
P/E (TTM)
29.3x
TTM · talc-charge impact
ROE
26.4%
TTM
Operating Margin
27.6%
TTM
Net Margin
21.5%
TTM
Dividend Yield
2.12%
64 straight years of hikes
Market Cap
$609.1B
As of 2026-07-17
Economic Moat · Key Business Segments
Johnson & Johnson is a global healthcare brand of more than 130 years, with a dual portfolio of pharmaceuticals (Innovative Medicine) and medical devices (MedTech). Profitability is high — $96.4B in revenue (TTM), a 27.6% operating margin, and a 68% gross margin — while FDA regulation and accumulated clinical data form entry barriers. It is a Dividend King with 64 straight years of increases (source: company IR · TradingView).
Brand power
A 130-year-plus global healthcare brand with top-tier trust and recognition.
Dual portfolio
Pharma and MedTech wings spread cyclical and patent risk.
Scale and switching costs
$96B in revenue, with hospital and device stickiness making switching costs high.
Regulatory barriers
FDA regulation and accumulated clinical data block new entrants.
10-Year Financial Trends
Revenue growth is modest at roughly +3% annualized over nine years, but the benefits of focusing on pharma and devices after the Kenvue spin-off are becoming visible. FY2025 revenue was $94.2B. Q2 2026 (reported Jul 15) revenue was $25.3B (+6.6% YoY) with operating income of $7.2B (+6.9% YoY), and the company raised its FY2026 guidance. Diluted EPS has swung sharply on one-off items — a 2017 tax charge ($0.48) and a 2024 talc provision ($5.79) — and spiked temporarily to $13.72 in 2023. As talc settlements progress, EPS is expected to normalize (source: SEC EDGAR 10-K · company IR).
10-Year Growth
Revenue$94.2B · CAGR +2.2%
Operating Income$25.5B · CAGR +6.3%
EPS$11.03 · CAGR +6.2%
10-Year Valuation
P/E (year-end)18.8x · avg 20.6x
ROE35.0% · avg 24.2%
Operating Margin27.1% · avg 25.4%
📊 Annual Data Table (JNJ) — expand/collapse
Year
Revenue (B$)
Op. Income (B$)
EPS ($)
P/E (x)
ROE (%)
Op. Margin (%)
2014
74.3
—
5.7
—
—
—
2016
70.1
—
5.56
—
—
—
2017
76.5
—
0.48
—
—
—
2018
81.6
—
5.61
—
—
—
2019
82.1
—
5.63
—
—
—
2021
82.6
20
7.81
21.9
25.9
25.5
2022
80
20.2
6.73
26.3
21.7
25.3
2023
85.2
21.7
13.72
11.4
18.3
25.5
2024
88.8
21
5.79
24.8
20.1
23.7
2025
94.2
25.5
11.03
18.8
35
27.1
— = no data for that year/metric (P/E omitted before EPS turned positive)
9-Year CAGR: Revenue +3.3% · Operating Income Limited data · Net Income +5.5% · EPS +7.1%
Sources: SEC EDGAR 10-K · stockanalysis · company IR. GAAP basis; EPS is diluted. Revenue and EPS are SEC-reported (non-consecutive years; 2015 and 2020 not included); P/E and ROE cover the last 5 years (stockanalysis). The 10-year operating-income series is omitted due to data limits.
Mega-Cap Value Metric Comparison
JNJ's combined pharma-and-device portfolio makes it highly stable, but at a 29x P/E it trades at a premium to Merck (~13x) and AbbVie (~21x). Its 27.6% operating margin is among the best in the peer group (source: TradingView · company filings).
Metric
★ JNJ
MRK
ABBV
P/E (TTM)
29.3
~13
~21
Operating Margin
27.6%
~28%
~26%
Dividend Yield
2.12%
~3.6%
~3.8%
P/E and operating margin = TTM · sources: TradingView · company filings, 2026-07-17.
Key Risk Factors (from 10-K)
●
Patent cliff— Intensifying biosimilar competition for Stelara ($10B+ in sales) threatens to erode revenue.Source: Company 10-K
●
Talc litigation— Uncertainty over the final settlement cost of talc-related litigation is a swing factor for when EPS normalizes.Source: Courts · company IR
●
Drug-pricing regulation (IRA)— U.S. drug-price negotiation pressure could squeeze pharmaceutical profitability.Source: Regulators
✦ ValueCrab Dashboard PreviewJNJ $253.04 +1.23% · as of 2026-07-17
Q. What are Johnson & Johnson's (JNJ) key value-investing metrics?P/E (TTM) 29.3, ROE 26.4%, operating margin 27.6%, net margin 21.5%, dividend yield 2.12%, and 64 consecutive years of dividend increases (sources: TradingView · company IR, as of 2026-07-17).
Q. How is JNJ as a dividend stock?As a Dividend King with 64 straight years of increases, its dividend stability is very high. Strong free cash flow funds both the dividend and R&D. (This is informational, not a buy or sell recommendation.)
Q. Why is EPS so uneven?One-off items — a 2017 tax charge and a 2024 talc-litigation provision — drive large swings in GAAP EPS. As the talc settlement progresses, EPS is expected to normalize.